Ultra‐high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma

Saito, Yuki; Kobayashi, Kenya; Fukuoka, Osamu; Sakai, Toshihiko; Yamamura, Koji; Ando, Mizuo; Kondo, Kenji

doi:10.1002/hed.27576

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, low pretreatment serum albumin levels in cancer patients are associated with poor survival [43][44][45], and low serum albumin levels are associated with poor response to various chemotherapies and tyrosine kinase inhibitors (TKIs) [46,47]. More recently, serum albumin levels were demonstrated to predict the prognosis of ICI therapy [30,32].…”

Section: Discussionmentioning

confidence: 99%

“…Serum albumin level has been identified as a prognostic factor in many malignant diseases [27][28][29]. Specifically, pretreatment serum albumin level was recently found to be useful for predicting the response to ICI treatment in various carcinomas, including head and neck cancer [30][31][32]. However, whether pretreatment serum albumin levels are associated with long-term survival in patients with R/M HNSCC treated with nivolumab has not yet been examined.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Suzuki,

Taguchi,

Kitabayashi

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Nivolumab has been shown to improve the overall survival (OS) of patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, there is a need to identify factors associated with long-term survival (beyond 2 years) in these patients. This study investigated the relationship between pretreatment factors and long-term survival in patients with R/M HNSCC treated with nivolumab. Methods: Forty-nine patients with R/M HNSCC who were treated with nivolumab were retrospectively reviewed. Baseline characteristics, clinical data, and survival outcomes were evaluated. Univariate and multivariate analyses were performed to identify factors associated with long-term survival (OS ≥ 2 years). Results: The median OS in the overall cohort was 11.0 months, and the 2-year survival rate was 34.7%. Long-term survivors (OS ≥ 2 years) had significantly higher proportions of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of 0 or 1, serum albumin levels ≥ 3.5 g/dL, and neutrophil-to-eosinophil ratio (NER) < 32.0 compared to non-long-term survivors. On multivariate analysis, serum albumin levels ≥ 3.5 g/dL, in addition to ECOG-PS score of 0 or 1, were independent predictors of long-term survival. Conclusions: Pretreatment serum albumin levels may be useful for predicting long-term survival in R/M HNSCC patients treated with nivolumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Suzuki,

Taguchi,

Kitabayashi

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Identifying factors for pembrolizumab eligibility in head and neck cancer

Miyamaru,

Murakami,

Nishimoto

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Although immune checkpoint inhibitors (ICIs) are used as first-line treatments for recurrent or metastatic head and neck cancer (R/M HNC), there are many cases where the treatment is ineffective, making the assessment of efficacy crucial. In this study, we examined factors associated with the therapeutic effects of pembrolizumab. Methods We retrospectively analyzed 54 patients with R/M HNC treated with pembrolizumab from January 2020 to December 2022. We investigated the relationship between survival rates and various factors such as the combined positive score (CPS), histological subtypes, recurrent lesions, details of administered agents, sequence of administration, history of cetuximab use, and presence of immune-related adverse events (irAEs). Results The overall survival rates at 1-, 2, and 3 years were 57.4%, 41.8%, and 32.3%, respectively. The response and disease control rates were 31.5% and 51.9%, respectively. In the univariate analysis, a CPS of 20 or higher, first-line treatment, no history of cetuximab use, and the presence of irAEs was associated with better survival rates, whereas in the multivariate analysis, the first two factors were significantly associated with better survival. In this study, 16 of 20 cases had a CPS of 50 or higher, and 7 had a CPS of 90 or higher, indicating that a large number of high CPS cases were included, which is believed to have contributed to the results of this study. Conclusion In patients with a CPS of 20 or higher, pembrolizumab can be administered as first-line treatment, with favorable expected therapeutic effects.

show abstract

Ultra‐high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma

Cited by 2 publications

References 28 publications

Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Identifying factors for pembrolizumab eligibility in head and neck cancer

Contact Info

Product

Resources

About